1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
Progressive Supranuclear Palsy Market Insight, Epidemiology and Market Forecast -2030

Progressive Supranuclear Palsy Market Insight, Epidemiology and Market Forecast -2030

  • January 2021
  • 127 pages
  • ID: 5879446
  • Format: PDF
  • Delve Insight

Summary

Table of Contents

‘Progressive Supranuclear Palsy–Market Insights, Epidemiology, and Market Forecast-2030’ report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology as well as the market trends of Progressive Supranuclear Palsy in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

The Progressive Supranuclear Palsy market report provides analysis regarding current treatment practices, emerging drugs like AZP2006, UCB0107, RT001 and other promising candidates like NBMIand Antisense oligonucleotide market share of the individual therapies, and historical, current and forecasted Progressive Supranuclear Palsy market size from 2017 to 2030, segmented by seven major markets.

The report also covers current Progressive Supranuclear Palsy treatment practice/algorithm, guidelines, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities. It assesses the underlying potential of the market.

Geography Covered
• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan

Study Period: 2017–2030

Progressive Supranuclear Palsy – Disease Understanding and Treatment Algorithm

Overview:

Progressive supranuclear palsy (PSP) is an uncommon degenerative neurological disorder—the disease results from damage to nerve cells in the brain—that causes the gradual deterioration of balance and walking; speech difficulties, trouble in swallowing, diminished vision, changes in mood and behavior, and cognitive impairment. The disorder’s long name indicates that the disease worsens (progressive) and causes weakness (palsy) by damaging certain parts of the brain above nerve cell clusters called nuclei (supranuclear). These nuclei mainly control eye movements. One of the classic signs of the disease is an inability to aim and move the eyes properly, which individuals may experience as blurring of vision. While the pattern of signs and symptoms can be quite different from person to person, the most frequent first symptom of PSP is a loss of balance while walking.

It was sometimes referred to as Steele–Richardson–Olszewski syndrome, reflecting the combined names of the scientists who defined the disorder. Progressive supranuclear palsy is characterized pathologically by four-repeat (4R) Tau deposition in various cell types and anatomical regions. The broad spectrum of syndromes that have been linked to PSP pathology also includes PSP-parkinsonism, a variant that presents with features suggestive of Parkinson’s disease (PD), pure akinesia with gait freezing, corticobasal syndrome, non-fluent variant primary progressive aphasia, behavioural variant frontotemporal dementia and even PSP presenting with cerebellar ataxia.

No specific laboratory tests or imaging approaches currently exist to diagnose PSP definitively. The disease is often difficult to diagnose because its symptoms can be very much like those of other movement disorders, and because some of the most characteristic symptoms may develop late or not at all.

Treatment:

While there is currently no disease-modifying therapy for PSP, some treatment strategies have been successful for symptomatic management. The most frequently prescribed medications for symptomatic management were drugs for movement disorders, anti-infectants, and anti-depressants.

This chapter covers the details of conventional and current medical therapies available for the treatment of Progressive Supranuclear Palsy. It also provides Progressive Supranuclear Palsy treatment guidelines across the United States and Europe.

Progressive Supranuclear Palsy market report gives a thorough understanding of the disease by including details such as disease definition, etiology, types, neurobiology, biomarkers and diagnosis. It also provides Progressive Supranuclear Palsy treatment pattern and treatment guidelines in the US and Europe.

Epidemiology:

The Progressive Supranuclear Palsy epidemiology chapters provide insights about historical and current Progressive Supranuclear Palsy patient pool and forecasted trends for every seven major countries. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. Progressive Supranuclear Palsy epidemiology is segmented by the prevalence of PSP, phenotype associated with PSP, the gender-specific prevalence of PSP and comorbidities associated with PSP. Besides, the report includes a thorough analysis of all segments.

According to the analyst, the total prevalent population of Progressive Supranuclear Palsy in seven major markets was 82,730 in 2017. These cases are expected to increase with a significant CAGR during the study period (2017–2030).

Among all the seven major markets, total prevalent cases for Progressive Supranuclear Palsy were highest in Japan, followed by the United States and Germany. Spain accounted for the least number of prevalent cases among the 7MM.

Drug Chapters:

This segment encloses the detailed analysis of the drugs in the Progressive Supranuclear Palsy pipeline. It also helps understand the Progressive Supranuclear Palsy clinical trial details, expressive pharmacological action, agreements of the included drug, and the latest news and press releases.

Treatment of PSP is symptomatic and supportive. There is no cure for the disease at the present time. Emerging therapies like AZP2006, UCB0107 and RT001 are expected to bring a positive shift to the overall market.

Market Outlook:
The market size of Progressive Supranuclear Palsy is expected to increase at a significant CAGR during the study period (2017–2030). Among all the seven major markets, the United States accounted for the largest Progressive Supranuclear Palsy market size followed by Japan. Among the EU5 countries, the United Kingdom had the largest market size, with USD 0.70 million in 2017 while Spain had the smallest market size of PSP, with USD 0.24 million in 2017.

Drugs Uptake:
This section focuses on the rate of uptake of the potential drugs in the Progressive Supranuclear Palsy market or expected to get launched in the market during the study period 2017–2030. The analysis covers Progressive Supranuclear Palsy market uptake by drugs; patient uptake by therapies; and sale of each drug.

It helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs based on market share and size. All of which will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

The dynamics of PSP market is anticipated to experience a major positive shift in the coming years owing to the expected launch of therapies like AZP2006, UCB0107 and RT001.

Progressive Supranuclear Palsy: Pipeline Development Activities

The report provides insights into different therapeutic candidates and also analyses the key players involved in developing targeted therapeutics.

Pipeline Development Activities:

The report covers the detailed information of collaborations, acquisition and merger, licensing, patent details, and emerging therapies, concerning Progressive Supranuclear Palsy.

KOL Views

To keep up with current market trends, we take KOLs and SME’s opinion working in Progressive Supranuclear Palsy domain through primary research to fill the data gaps and validate our secondary research. It will support the clients in assessing potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis

We have performed the competitive and market Intelligence analysis of the Progressive Supranuclear Palsy Market by using various competitive intelligence tools that include SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies etc. Besides, the inclusion of the analysis entirely depends upon the data availability.

Report Highlights:
• In the coming years, Progressive Supranuclear Palsy market scenario is expected to experience a positive shift across the 7MM due to a robust pipeline.

• Our in-depth analysis of the pipeline assets across different stages of development (Phase II and Phase III), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

Progressive Supranuclear Palsy Report Insights:
• Patient Population
• Therapeutic Approaches
• Progressive Supranuclear Palsy Pipeline Analysis
• Progressive Supranuclear Palsy Market Size and Trends
• Market Opportunities
• Impact of upcoming Therapies

Progressive Supranuclear Palsy Report Key Strengths:
• 11 years Forecast
• 7MM Coverage
• Progressive Supranuclear Palsy Epidemiology Segmentation
• Key Cross Competition
• Market Size by Therapies
• Drugs Uptake

Progressive Supranuclear Palsy Report Assessment:
• Pipeline Product Profiles

• Key Products and Key Players
• Market Drivers and Barriers

Key Questions

Market Insights:
• What was the Progressive Supranuclear Palsy market share (%) distribution in 2017 and how it would look like in 2030?
• What would be the Progressive Supranuclear Palsy total market size as well as market size by therapies across the 7MM during the forecast period (2017–2030)?
• What are the key findings pertaining to the market across 7MM and which country will have the largest Progressive Supranuclear Palsy market size during the forecast period (2017–2030)?
• At what CAGR, the Progressive Supranuclear Palsy market is expected to grow in 7MM during the forecast period (2017–2030)?
• What would be the Progressive Supranuclear Palsy market outlook across the 7MM during the forecast period (2017–2030)?
• What would be the Progressive Supranuclear Palsy market growth till 2030, and what will be the resultant market Size in the year 2030?
• How would the market drivers, barriers and future opportunities affect the market dynamics and subsequent analysis of the associated trends?

Epidemiology Insights:
• What are the disease risk, burden and unmet needs of Progressive Supranuclear Palsy?
• What is the historical Progressive Supranuclear Palsy patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
• What would be the forecasted patient pool of Progressive Supranuclear Palsy in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
• What will be the growth opportunities in the 7MM concerning the patient population pertaining to Progressive Supranuclear Palsy?
• Out of all 7MM countries, which country would have the highest prevalent population of Progressive Supranuclear Palsy during the forecast period (2017–2030)?
• At what CAGR the population is expected to grow in 7MM during the forecast period (2017–2030)?

Current Treatment Scenario, Marketed Drugs, and Emerging Therapies:
• What are the current options for Progressive Supranuclear Palsy treatment, along with the approved therapy?
• What are the current treatment guidelines for the treatment of Progressive Supranuclear Palsy in the US, Europe, and Japan?
• How many companies are developing therapies for the treatment of Progressive Supranuclear Palsy?
• How many therapies are developed by each company for Progressive Supranuclear Palsy?
• How many are emerging therapies in mid-stage, and late stage of development for Progressive Supranuclear Palsy treatment?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Progressive Supranuclear Palsy therapies?
• What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Progressive Supranuclear Palsy and their status?
• What are the key designations that have been granted for the emerging therapies for Progressive Supranuclear Palsy?
• What is the global historical and forecasted market of Progressive Supranuclear Palsy?

Reasons to buy:
• The report will help in developing business strategies by understanding trends shaping and driving the Progressive Supranuclear Palsy market
• To understand the future market competition in the Progressive Supranuclear Palsy market and Insightful review of the key market drivers and barriers
• Organize sales and marketing efforts by identifying the best opportunities for Progressive Supranuclear Palsy in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom), and Japan
• Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
• Organize sales and marketing efforts by identifying the best opportunities for Progressive Supranuclear Palsy market
• To understand the future market competition in the Progressive Supranuclear Palsy market

Which geography accounted for the largest Progressive Supranuclear Palsy market size?

The United States accounted for the largest Progressive Supranuclear Palsy market size.

What is forecasted Progressive Supranuclear Palsy size in 2030?

The analyst estimates an increase in Progressive Supranuclear Palsy Market Size during the study period, 2017–2030

What are the present Progressive Supranuclear Palsy market drivers?

Increasing Government Initiatives, New emerging diagnostic methods, Implementation of large Randomized Clinical Trials
What are the Progressive Supranuclear Palsy market barriers?

Poor Prognosis, Limitations in symptomatic treatment, Delayed Diagnosis, Lack of efficacious treatment, Challenges in measuring the efficacy, High costs for therapies

How many companies are developing drugs for Progressive Supranuclear Palsy?

Currently, three key pharma players are developing the drug for Progressive Supranuclear Palsy

Which are the leading companies in Progressive Supranuclear Palsy market?

Key Players – AlzProtect, UCB Biopharma, Retrotope

How is epidemiology segmented for Progressive Supranuclear Palsy?

Prevalence of PSP, phenotype associated with PSP, gender-specific prevalence of PSP and comorbidities associated with PSP

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

ReportLinker may already be registered as a supplier with your company. If you want to Order by PO, check with us first and we'll let you know if we are a registered supplier and what the vendor number is. Otherwise, we'll provide you with the necessary information to register ReportLinker as a vendor.

Ahmad helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers

UBLITUXIMAB + UMBRALISIB - Emerging Insight and Market Forecast - 2030

  • $ 3250
  • February 2021
  • 30 pages

“UBLITUXIMAB + UMBRALISIB - Emerging Insight and Market Forecast - 2030” the report provides comprehensive insights about an investigational product for Diffuse Large B-Cell Lymphoma in 7 Major Markets. ...

  • Europe
  • Japan
  • Lymphoma
  • Therapy
  • Industry analysis
  • Health Expenditure

Global Biophotonics Industry $ 5450 April 2021


ref:plp2020

Reportlinker.com © Copyright 2021. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on